Stock listing

Frankfurt:69C Tvardi Therapeutics, Inc. Aktie

German listing (Frankfurt) of Tvardi Therapeutics, Inc. · home listing NASDAQ:TVRD

Follow Tvardi Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:69C

€0.78 EUR +0.04 (+5.4%)

Close on Nov 20, 2026

Past year -65.3% · daily closes, Nov 20, 2025 – Nov 12, 2026, adjusted for splits
Day range
€0.71 – €0.78 EURNov 20, 2026
Market cap
€10.40M EURAt the close on Nov 20, 2026 · price × 13.34M shares outstanding
52-week range
€0.567 – €4.03 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€250 EURMedian day 0 shares · 49 days with no trades · last 3 months, Aug 20, 2026 – Nov 12, 2026
Tvardi Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TVRD · Home$0.989 USD-0.051 (-4.9%)159,935$0.920$1.000$0.900$1.040Close on Nov 20, 2026
Frankfurt:69C€0.78 EUR+0.04 (+5.4%)—€0.71€0.78€0.71€0.74Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 12, 2026 · FWB:69C · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.98-0.126-11.4%€1.05€1.05€0.9750
€1.106-0.053-4.6%€1.115€1.216€1.090
€1.159+0.248+27.2%€1.153€1.17€1.1411,578
€0.911+0.203+28.7%€0.717€0.915€0.6940
€0.708+0.05+7.6%€0.611€0.72€0.6112,800
€0.658+0.002+0.3%€0.621€0.659€0.61516
€0.656+0.063+10.6%€0.596€0.656€0.58916
€0.593-0.028-4.5%€0.569€0.594€0.5670
€0.621-0.003-0.5%€0.709€0.709€0.6190
€0.624-0.048-7.1%€0.624€0.624€0.6240
€0.672+0.038+6.0%€0.666€0.697€0.6635,200
€0.634-0.031-4.7%€0.634€0.634€0.6342,400
€0.665-0.012-1.8%€0.634€0.665€0.6310
€0.677-0.039-5.4%€0.684€0.686€0.67752
€0.716-0.032-4.3%€0.716€0.716€0.7160
€0.748-0.079-9.6%€0.748€0.748€0.7480
€0.827+0.007+0.9%€0.74€0.829€0.7340
€0.82+0.046+5.9%€0.71€0.824€0.7090
€0.774-0.037-4.6%€0.759€0.782€0.7560
€0.811-0.006-0.7%€0.811€0.811€0.8110
€0.817+0.04+5.1%€0.747€0.819€0.7410
€0.777-0.021-2.6%€0.777€0.777€0.7770
€0.798+0.027+3.5%€0.798€0.798€0.7980
€0.771-0.036-4.5%€0.771€0.771€0.7710
€0.807-0.022-2.7%€0.807€0.807€0.8072
€0.829-0.028-3.3%€0.829€0.829€0.8291,276
€0.857-0.032-3.6%€0.818€0.862€0.8030
€0.889-0.04-4.3%€0.875€0.895€0.8680
€0.929+0.011+1.2%€0.929€0.929€0.9290
€0.918-0.073-7.4%€0.947€0.953€0.9130
€0.991+0.017+1.7%€0.964€1.005€0.9580
€0.974-0.047-4.6%€0.974€0.974€0.9740
€1.021+0.062+6.5%€1.021€1.021€1.0210
€0.959+0.09+10.4%€0.959€0.959€0.9590
€0.869+0.002+0.2%€0.788€0.88€0.7884,400
€0.867-0.241-21.8%€0.998€0.999€0.8620
€1.108-0.242-17.9%€1.211€1.22€1.1070
€1.35+0.042+3.2%€1.261€1.363€1.2430
€1.308-0.003-0.2%€1.28€1.309€1.2740
€1.311-0.059-4.3%€1.259€1.311€1.25290
€1.370.000.0%€1.37€1.37€1.370
€1.37-0.043-3.0%€1.37€1.37€1.370
€1.413-0.127-8.2%€1.428€1.436€1.4110
€1.54+0.113+7.9%€1.483€1.56€1.4720
€1.427-0.261-15.5%€1.427€1.427€1.4270
€1.688+0.173+11.4%€1.449€1.711€1.436819
€1.515-0.049-3.1%€1.512€1.516€1.510
€1.564+0.081+5.5%€1.482€1.572€1.4690
€1.483+0.052+3.6%€1.483€1.483€1.4830
€1.431-0.04-2.7%€1.431€1.431€1.4310
€1.471+0.122+9.0%€1.471€1.471€1.4710
€1.349-0.044-3.2%€1.349€1.349€1.3490
€1.393-0.01-0.7%€1.393€1.393€1.3930
€1.403+0.018+1.3%€1.403€1.403€1.4030
€1.385+0.001+0.1%€1.385€1.385€1.3850
€1.384-0.031-2.2%€1.384€1.384€1.3840
€1.415+0.052+3.8%€1.415€1.415€1.4150
€1.363-0.073-5.1%€1.363€1.363€1.3630
€1.436+0.033+2.4%€1.436€1.436€1.4360
€1.403-0.056-3.8%€1.403€1.403€1.4030
€1.459-0.021-1.4%€1.459€1.459€1.4590
Ticker
Frankfurt:69C
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Tvardi Therapeutics, Inc. news

Tvardi Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 102 in all · newest Nov 19, 2026 · oldest 2021
Calls
14 calls with a replay · 14 with a transcript · latest Mar 4, 2024
Decks
11 decks · latest September 2026

Where Tvardi Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TVRD · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A414VYLang & SchwarzGermanyEUR
LS Exchange:A414VYLS ExchangeGermanyEUR
Frankfurt:69C · This pageFrankfurtGermanyEUR
gettex:69CgettexGermanyEUR
Tradegate:69CTradegateGermanyEUR
Stuttgart:69C0StuttgartGermanyEUR
LSE:0HTCLSEUnited KingdomUSD
BOATS:TVRDBOATSUnited StatesUSD
BX Swiss:TVRDBX SwissSwitzerlandCHF
Munich:69CMunichGermanyEUR

Valuation

Price/book 0.9× against a median of 2.7×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$9.05M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tvardi Therapeutics, Inc. · NASDAQ:TVRDUS$13.22M−US$9.05Mn/an/an/a0.9×n/a0.0×1.89
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.47MUS$15.05Mn/an/a52.8×3.6×n/a0.4×n/a
BioInvent International AB · OMXSTO:BINVUS$13.45M−US$6.62Mn/a−1.7×n/a0.7×n/a0.1×n/a
Thalia Therapeutics PLC · LSE:THATUS$13.36MUS$11.39Mn/a1,199×n/a4.2×n/a0.0×n/a
Celyad Oncology SA · EURONEXT:CYADUS$13.31MUS$13.21M14.6×573×n/a9.7×n/a0.0×n/a
Defence Therapeutics Inc Class A · CSE:DTCUS$13.27MUS$13.16Mn/an/an/a5.4×n/a0.5×0.74
Diamyd Medical AB Class B · OMXSTO:DMYD_BUS$13.22M−US$16.66Mn/a−357×n/a0.6×n/a0.0×n/a
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Median of the othersUS$13.40MUS$12.05M7.5×6.0×52.8×2.7×−204.1%0.0×1.31

Forecasts

5 strong buy · 2 buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
8.88 USD · Analysts' mean
EPS, year to Dec 2026
-2.25 · 7 analysts

Team and board

Officers

OfficerRole
Imran AlibhaiChief Executive Officer
Dan ConnChief Financial Officer
Kari Anne RowlandVice President, Clinical Operations
Sofia de AchavalVice President, Development
Stephen O’BrienVP, Finance and Corporate Controller
Yixin Joseph ChenVice President, CMC
David TweardyCo-Founder
John KauhChief Medical Officer
Michael T. LewisCo-Founder & Professor, Molecular and Cellular Biology and Radiology
Ron DePinhoCo-Founder & Chairman of Scientific Advisory Board

Board

DirectorRole
Ron DePinhoCo-Founder & Chairman of Scientific Advisory Board
Sujal ShahChairman of the Board
Cynthia SmithBoard Member
David TweardyCo-Founder
Imran AlibhaiChief Executive Officer
Michael T. LewisCo-Founder & Professor, Molecular and Cellular Biology and Radiology
Michael WyzgaBoard Member
Susan ShiffBoard Member
Wallace HallBoard Member

Events

Calls

CallWhenStatus
Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings CallMon, Mar 04, 2024 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q3 2023 Earnings CallMon, Nov 13, 2023 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings CallMon, Aug 07, 2023 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings CallMon, May 15, 2023 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings CallMon, Mar 06, 2023 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings CallMon, Nov 07, 2022 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q1 2022 Earnings CallMon, May 09, 2022 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q4 2021 Earnings CallTue, Mar 01, 2022 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings CallMon, Nov 08, 2021 · 4:30 PM ETReplay
All 14 calls
CallWhenStatus
Cara Therapeutics, Inc. (CARA) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q1 2021 Earnings CallMon, May 10, 2021 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q4 2020 Earnings CallThu, Feb 25, 2021 · 4:30 PM ETReplay
Cara Therapeutics, Inc. (CARA) Q3 2020 Earnings CallMon, Nov 09, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open+2.2%
Q2 2026Aug 14, 2026 · Before open+7.3%
Q1 2026May 8, 2026−5.9%
Q4 2025Mar 31, 2026 · After close−5.7%
Q3 2025Nov 13, 2025 · After close−1.9%
Q2 2025Aug 14, 2025 · After close+0.9%
Q1 2025May 13, 2025 · After close−0.7%
Q4 2024Feb 26, 2025−3.6%
Q3 2024Nov 29, 2024+1.0%
Q2 2024Aug 5, 2024+4.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024+1.1%
Q4 2023Mar 4, 2024−4.2%
Q3 2023Nov 13, 2023+4.3%
Q2 2023Aug 7, 2023−6.1%
Q1 2023May 15, 2023+11.3%
Q4 2022Mar 6, 2023−34.9%
Q3 2022Nov 7, 2022+3.6%
Q2 2022Aug 8, 2022+4.8%
Q1 2022May 9, 2022+14.7%
Q4 2021Mar 1, 2022+11.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck63 slidesSeptember 2026
Technical Presentation (August 2026)Technical38 slidesAug 19, 2026
Investor Presentation (July 2026)Investor deck63 slidesJul 30, 2026
Investor Presentation (July 2026)Investor deck56 slidesJul 7, 2026
Investor Presentation (January 2026)Investor deck36 slidesJan 16, 2026
Investor Presentation (November 2025)Investor deck28 slidesNov 19, 2025
Investor Presentation (June 2025)Investor deck38 slidesJun 9, 2025
Cara Therapeutics — Merger or Acquisition (April 2025)Merger or acquisition37 slidesApr 11, 2025
Cara Therapeutics — Merger or Acquisition (January 2025)Merger or acquisition36 slidesJan 21, 2025
Cara Therapeutics — Merger or Acquisition (December 2024)Merger or acquisition31 slidesDec 20, 2024
All 11 decks
DeckKindSlidesDate
Cara Therapeutics — Merger or Acquisition (December 2024)Merger or acquisition31 slidesDec 18, 2024

Open Decks

Financings

RaiseDate
Private placement of shares
Closed: US$28M raised
Use of proceeds: With both companies' cash, to fund the combined company's operating expenses and capital expenditures into the second half of 2026
Dec 18, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Cara Therapeutics, Inc. Priced at US$11.00 a share on Jan 30, 2014.

Price
US$11.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$55 million
Underwriters' option
Up to 750,000 more shares
Underwriters
Stifel, Piper Jaffray, Canaccord Genuity, Needham & Company, Janney Montgomery Scott · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceOct 4, 2013
Filed publiclyNov 8, 2013
Amended twiceNewest Jan 17, 2014
Shares registered with an exchangeJan 27, 2014
Declared effective by the SECJan 30, 2014
Final prospectus, with the priceFeb 3, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Feb 3, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue07.14M21.0M41.9M23.0M135.1M19.9M13.5M911.0K86.0K
Cost of revenue95.0K812.0K6.43M7.51M0
Gross profit-95.0K6.33M14.5M34.4M21.5M
Research and development18.0M23.6M108.5M91.9M82.7M107.9M113.8M75.5M48.5M49.3M
Selling, general and administrative8.74M4.46M2.80M2.73M
Operating income-26.7M-28.1M-121.5M-87.5M-89.1M5.38M-111.7M-77.4M-59.5M-58.4M
Depreciation and amortization95.0K95.0K259.0K248.0K248.0K209.0K198.0K370.0K495.0K1.47M
EBITDA-26.7M-28.0M-121.2M-87.3M-88.8M5.59M-111.5M-77.0M-59.0M-56.9M
Interest expense8.47M03.00K
Income before tax-18.2M-71.3M-118.5M-85.5M-88.4M7.72M-107.2M-74.4M-58.3M-57.7M
Income tax00000-691.0K-816.0K-389.0K-204.0K-468.0K
Net income-18.2M-29.4M-118.5M-85.5M-88.4M8.41M-106.4M-74.0M-58.1M-57.3M
Earnings per share, basic-2.46-11.42-26.26-19.12-1.740.18-2.49-2.06-1.86-2.10
Earnings per share, diluted-3.26-11.42-26.26-19.12-1.740.18-2.49-2.06-1.86-2.10

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents20.7M31.6M51.8M63.7M13.5M31.7M18.3M15.1M9.39M12.1M
Short-term investments10.1M049.0M22.3M153.6M149.2M136.7M146.3M83.2M46.2M
Receivables407.0K2.77M3.26M1.15M2.06M
Inventory900.0K2.82M2.38M2.58M
Current assets31.5M31.7M116.2M168.9M173.3M195.1M165.7M168.1M95.1M61.4M
Property, plant and equipment52.0K84.0K3.32M426.0K631.0K840.0K700.0K880.0K1.18M1.61M
Total assets32.1M35.2M125.8M182.2M247.1M271.2M233.0M190.8M97.0M63.8M
Accounts payable3.22M2.19M11.6M9.60M5.63M4.89M9.10M4.37M3.83M4.74M
Current liabilities11.0M10.4M25.6M23.5M17.6M18.5M42.9M40.4M8.51M11.5M
Long-term debt30.3M
Total debt201.0K44.4M368.0K2.37M3.67M5.28M
Total liabilities11.1M40.8M68.8M23.5M19.5M22.2M
Shareholders' equity20.9M-91.1M-62.1M158.8M227.5M249.0M186.7M133.6M86.8M50.7M
Shares outstanding9.38M2.57M4.54M53.8M53.5M49.9M46.7M39.5M32.7M27.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-23.5M-18.3M-92.1M-78.7M-60.1M-5.49M-109.2M-22.3M-54.8M-47.4M
Capital spending0-1.05M-2.38M-43.0K-39.0K-349.0K-18.0K-73.0K-58.0K-717.0K
Free cash flow-23.5M-19.4M-94.5M-78.8M-60.1M-5.84M-109.2M-22.4M-54.9M-48.1M
Cash from investing-10.1M48.7M43.5M128.7M-4.75M-20.3M-30.5M-82.8M-36.5M45.0M
Cash from financing22.7M27.0M38.2M311.0K46.6M39.1M142.6M110.8M87.9M123.0K
Change in cash-10.9M8.70M-10.5M50.3M-18.2M13.4M2.86M5.69M-2.70M-3.01M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
8-K · Current reportJul 30, 2026Current reportSEC
8-K · Current reportJul 17, 2026Current reportSEC
424B5 · ProspectusJul 17, 2026Offer documentSEC
8-K · Current reportJul 7, 2026Current reportSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 14, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 13, 2026Other filingsSEC
POS AM · Amendment to an effective registrationMay 8, 2026Offer documentSEC
CORRESP · Letter to the SECMay 8, 2026Other filingsSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026ResultsSEC
UPLOAD · Letter from the SECMay 7, 2026Other filingsSEC
S-3 · Registration statementMay 1, 2026Offer documentSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansApr 1, 2026Offer documentSEC
POS EXApr 1, 2026Other filingsSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
424B3 · ProspectusMar 6, 2026Offer documentSEC
8-K · Current reportMar 6, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
8-K · Current reportJan 16, 2026Current reportSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
8-K · Current reportNov 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
424B3 · ProspectusNov 13, 2025Offer documentSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
S-8 · Registration statement for employee plansOct 20, 2025Offer documentSEC
S-1/A · Registration statement, amendedOct 20, 2025Offer documentSEC
8-K · Current reportOct 14, 2025Current reportSEC
S-1/A · Registration statement, amendedOct 7, 2025Offer documentSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 8, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
8-K · Current reportJul 14, 2025Management or board changeSEC
8-K · Current reportJun 9, 2025Current reportSEC
UPLOAD · Letter from the SECJun 5, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeJun 2, 2025Big-stake noticeSEC
S-1 · Registration statementMay 30, 2025Offer documentSEC
8-K · Current reportMay 27, 2025Current reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
8-K/A · Current report, amendedMay 13, 2025Acquisition or disposalSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
4/A · Change in ownership, amendedMay 2, 2025Insider tradeSEC
4/A · Change in ownership, amendedMay 2, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 2, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 2, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 22, 2025Big-stake noticeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 17, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 16, 2025Big-stake noticeSEC
8-K · Current reportApr 15, 2025Acquisition or disposalSEC
8-K · Current reportApr 11, 2025Current reportSEC
8-K · Current reportApr 1, 2025Meeting outcomeSEC
425Mar 24, 2025Other filingsSEC
8-K · Current reportMar 24, 2025Current reportSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
SEC STAFF LETTERFeb 19, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2025Other filingsSEC
424B3 · ProspectusFeb 14, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 14, 2025Other filingsSEC
S-4/A · Registration statement, amendedFeb 14, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 13, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 11, 2025Other filingsSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
S-4/A · Registration statement, amendedJan 27, 2025Offer documentSEC
CORRESP · Letter to the SECJan 24, 2025Other filingsSEC
425Jan 21, 2025Other filingsSEC
8-K · Current reportJan 21, 2025Current reportSEC
425Jan 17, 2025Other filingsSEC
8-K · Current reportJan 17, 2025Current reportSEC
SEC STAFF LETTERJan 17, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2025Other filingsSEC
425Dec 30, 2024Other filingsSEC
8-K · Current reportDec 30, 2024Current reportSEC
425Dec 20, 2024Other filingsSEC
8-K/A · Current report, amendedDec 20, 2024Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 18, 2024Big-stake noticeSEC
S-4 · Registration statementDec 18, 2024Offer documentSEC
425Dec 18, 2024Other filingsSEC
8-K · Current reportDec 18, 2024Material contractSEC
8-K · Current reportNov 22, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
SC 13D · Big-stake noticeOct 30, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
4 · Change in ownershipAug 2, 2024Insider tradeSEC
8-K · Current reportAug 1, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedJul 8, 2024Big-stake noticeSEC
8-K · Current reportJun 18, 2024Current reportSEC
8-K · Current reportJun 12, 2024Current reportSEC
424B5 · ProspectusJun 7, 2024Offer documentSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
4 · Change in ownershipMay 6, 2024Insider tradeSEC
DEFA14A · Additional proxy materialApr 22, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 22, 2024Annual reportSEC
DEF 14A · Proxy statementApr 22, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
8-K · Current reportMar 22, 2024Management or board changeSEC
S-8 · Registration statement for employee plansMar 6, 2024Offer documentSEC
10-K · Annual reportMar 6, 2024Annual reportSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
8-K · Current reportMar 4, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
8-K · Current reportFeb 2, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 29, 2024Big-stake noticeSEC
8-K · Current reportJan 22, 2024Current reportSEC
8-K · Current reportDec 18, 2023Current reportSEC
8-K · Current reportNov 13, 2023Current reportSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
8-K · Current reportNov 2, 2023Material contractSEC
8-K · Current reportAug 7, 2023Current reportSEC
10-Q · Quarterly reportAug 7, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023ResultsSEC
4 · Change in ownershipAug 4, 2023Insider tradeSEC
4 · Change in ownershipAug 4, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2023Insider tradeSEC
8-K · Current reportAug 3, 2023Management or board changeSEC

This page holds 200 of 812 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tvardi Therapeutics, Inc.’s releases · as of Nov 10, 2026

Common shares
13,363,391
Fully diluted
13,363,391

Fully diluted

LineSharesAs of
Common shares13,363,391Nov 10, 2026

Share count over time

CountShares
Nov 10, 202613,363,391
Sep 30, 202613,345,956

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Slate Path Capital LP704K5.3%US$880KSep 30, 2026
Vanguard420K3.1%US$525KSep 30, 2026
Raymond James Financial Inc279K2.1%US$348KSep 30, 2026
Two Sigma241K1.8%US$302KSep 30, 2026
American Financial Group Inc224K1.7%US$280KSep 30, 2026
JPMorgan202K1.5%US$259KSep 30, 2026
Captrust Financial Advisors201K1.5%US$251KSep 30, 2026
Renaissance Technologies134K1.0%US$168KSep 30, 2026
Bank of America132K0.99%US$165KSep 30, 2026
Geode Capital121K0.90%US$151KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Silvercrest Asset Management Group LLC101K0.76%US$126KSep 30, 2026
BlackRock95,2970.71%US$119KSep 30, 2026
Verition Fund Management LLC87,0000.65%US$109KSep 30, 2026
Bridgeway Capital Management, LLC80,0000.60%US$100KSep 30, 2026
Morgan Stanley78,9540.59%US$98,693Sep 30, 2026
Duncan Williams Asset Management, LLC63,2410.47%US$79,051Sep 30, 2026
Gsa Capital Partners LLP58,3520.44%US$73,000Sep 30, 2026
Hrt Financial LP48,8530.37%US$61,000Sep 30, 2026
Diadema Partners LP48,4910.36%US$60,614Sep 30, 2026
LPL Financial LLC39,6100.30%US$49,513Sep 30, 2026
State Street33,9000.25%US$42,375Sep 30, 2026
Cantor Fitzgerald, L. P.30,0000.22%US$37,500Sep 30, 2026
Arax Advisory Partners29,3500.22%US$36,688Sep 30, 2026
Susquehanna25,4220.19%US$31,778Sep 30, 2026
Northern Trust21,8280.16%US$27,285Sep 30, 2026
NewEdge Advisors, LLC21,5130.16%US$26,891Sep 30, 2026
Brown Advisory Inc21,2000.16%US$26,500Sep 30, 2026
Curi Capital, LLC15,5000.12%US$19,375Sep 30, 2026
Brookstone Capital Management12,7640.10%US$15,955Sep 30, 2026
Persistent Asset Partners Ltd12,3290.09%US$15,411Sep 30, 2026
Goldman Sachs11,0000.08%US$13,750Sep 30, 2026
Kestra Advisory Services, LLC10,0440.08%US$12,555Sep 30, 2026
Russell Investments Group, Ltd.7,9800.06%US$9,975Sep 30, 2026
Tower Research Capital LLC (TRC)5,3590.04%US$6,699Sep 30, 2026
Caitong International Asset Management Co., Ltd1,228<0.01%US$1,535Sep 30, 2026
US Bancorp \de\1,000<0.01%US$1,250Sep 30, 2026
Farther Finance Advisors, LLC1,000<0.01%US$1,250Sep 30, 2026
Fortitude Family Office, LLC403<0.01%US$504Sep 30, 2026
RBC370<0.01%Sep 30, 2026
Group One Trading LLC214<0.01%US$268Sep 30, 2026
BNP Paribas196<0.01%US$245Sep 30, 2026
Allworth Financial LP141<0.01%US$177Sep 30, 2026
UBS48<0.01%US$60Sep 30, 2026
Jones Financial Companies Lllp46<0.01%US$58Sep 30, 2026
Osaic Holdings, Inc.37<0.01%US$46Sep 30, 2026
Simplex Trading, LLC36<0.01%US$45Sep 30, 2026
McIlrath & Eck, LLC20<0.01%US$25Sep 30, 2026
PNC Financial Services Group, Inc.17<0.01%US$21Sep 30, 2026
Kiker Wealth Management, LLC13<0.01%US$16Sep 30, 2026
Leonteq Securities AG12<0.01%US$15Sep 30, 2026

This page holds 50 of 60 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund258K1.9%US$491KJun 30, 2026
Vanguard Extended Market Index Fund85,9560.64%US$163KJun 30, 2026
Fidelity Extended Market Index Fund50,5170.38%US$171KMay 31, 2026
Vanguard Russell 2000 Index Fund30,5580.23%US$103KMay 31, 2026
Fidelity Total Market Index Fund14,4390.11%US$48,804May 31, 2026
Fidelity Series Total Market Index Fund12,1810.09%US$41,172May 31, 2026
iShares Russell 2000 ETF8,8730.07%US$16,859Jun 30, 2026
Fidelity Nasdaq Composite Index Fund6,4500.05%US$21,801May 31, 2026
Vanguard Russell 2000 Value Index Fund3,8200.03%US$12,912May 31, 2026
iShares Russell 2000 Value ETF2,6070.02%US$4,953Jun 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Bridge Builder Small/Mid Cap Value Fund1,9750.01%US$3,753Jun 30, 2026
Small Cap Index Fund1,3880.01%US$4,691May 31, 2026
iShares Micro-Cap ETF1,225<0.01%US$2,328Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund471<0.01%US$1,592May 31, 2026
Master Small Cap Index Series402<0.01%US$764Jun 30, 2026
EQ/2000 Managed Volatility Portfolio384<0.01%US$730Jun 30, 2026
ProShares Russell 2000 High Income ETF284<0.01%US$960May 31, 2026
iShares Russell 2000 Growth ETF272<0.01%US$517Jun 30, 2026
ProShares UltraPro Russell2000222<0.01%US$750May 31, 2026
ProShares Ultra Russell2000220<0.01%US$744May 31, 2026
Bridge Builder Small/Mid Cap Growth Fund193<0.01%US$367Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund122<0.01%US$232Jun 30, 2026
Destinations Small-Mid Cap Equity Fund115<0.01%US$389May 31, 2026
ATM Small Cap Managed Volatility Portfolio78<0.01%US$148Jun 30, 2026
NVIT Small Cap Index Fund68<0.01%US$129Jun 30, 2026
1290 VT Micro Cap Portfolio63<0.01%US$120Jun 30, 2026
Small-Cap Index Portfolio63<0.01%US$120Jun 30, 2026
1290 VT Small Cap Value Portfolio45<0.01%US$86Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND39<0.01%US$82Jul 31, 2026
BlackRock Small Cap Index V.I. Fund31<0.01%US$59Jun 30, 2026
PD Small-Cap Value Index Portfolio27<0.01%US$51Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio13<0.01%US$25Jun 30, 2026
Small-Cap Equity Portfolio11<0.01%US$21Jun 30, 2026
ProShares Hedge Replication ETF6<0.01%US$20May 31, 2026
Goldman Sachs Absolute Return Tracker Fund4<0.01%US$8Jun 30, 2026
ProShares Russell 2000 Dynamic Buffer ETF1<0.01%US$3May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Sporos Bioventures LLC8.95%838KApr 15, 2025Schedule 13G
Solas Tvardi Sidecar LLC8.10%761KApr 15, 2025Schedule 13G
Slate Path Capital LP7.50%704KJun 30, 2025Schedule 13G
David J. Tweardy7.00%652KApr 15, 2025Schedule 13G
Vifor (International) Ltd.2.20%205KApr 15, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cynthia Smith
Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least Aug 11, 2022); Protara Therapeutics, Inc. (Director · Since at least Jan 29, 2021); Spero Therapeutics, Inc. (Director · Since at least Mar 19, 2019); Akebia Therapeutics, Inc. (Senior Vice President, Market Access and Commercial Development · Since at least Aug 28, 2018); Dicerna Pharmaceuticals Inc (Director · Aug 13, 2018 – Dec 28, 2021 · Past); Alpine Immune Sciences Inc (Director · Nov 1, 2016 – Nov 1, 2016 · Past); ZS Pharma Inc (Chief Commercial Officer · Jun 17, 2014 – Dec 17, 2015 · Past)
Board Member · Since at least Apr 15, 2025
Edward Hurwitz
Other companies: Dyne Therapeutics, Inc. (Director · Since at least Jul 31, 2020); MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past)
Director · Jan 30, 2014 – Feb 5, 2014 · Past
Helen M. Boudreau
Other companies: Rallybio Corporation (Board Member · Since at least Jul 29, 2021); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past)
Director · Aug 2, 2023 – Jun 4, 2024 · Past
Mani Mohindru
Other companies: Cardiff Oncology, Inc. (President & Chief Executive Officer · Since at least Jun 10, 2021); CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Curis, Inc. (Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past)
CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past
Martin Vogelbaum
Other companies: Rocket Pharmaceuticals, Inc. (Director · Feb 17, 2015 – Jun 24, 2015 · Past); NephroGenex Inc (Director · Feb 10, 2014 – May 15, 2014 · Past); MiddleBrook Pharmaceuticals Inc (Director · Apr 20, 2007 – Jun 23, 2009 · Past)
Director · Jan 30, 2014 – Jun 4, 2024 · Past
Michael Wyzga
Other companies: Mereo BioPharma Group plc (Director · Since at least Feb 26, 2026); X4 Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2025); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past)
Board Member · Since at least Apr 15, 2025
Ryan Maynard
Other companies: Foghorn Therapeutics Inc. (Chief Financial Officer · Since at least Feb 23, 2026); Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Rigel Pharmaceuticals, Inc. (EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past)
CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past
Lisa von Moltke
Other companies: Zenas BioPharma, Inc. (Head of Research and Development and Chief Medical Officer · Since at least Mar 17, 2025); Seres Therapeutics, Inc. (See Remarks · Apr 6, 2020 – Feb 15, 2025 · Past)
Director · Nov 1, 2022 – Jun 4, 2024 · Past
Harrison M Bains Jr
Other companies: BG Medicine Inc (Director · Jun 12, 2013 – Jun 3, 2014 · Past)
Director · Jul 16, 2014 – Jun 1, 2023 · Past
Jeffrey L Ives
Other companies: Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021)
Director · Jul 16, 2014 – Jun 4, 2024 · Past
All 36 people
PersonSeat
Joana Goncalves
Other companies: Oruka Therapeutics, Inc. (Chief Medical Officer · Since at least Aug 29, 2024)
CHIEF MEDICAL OFFICER · Oct 22, 2018 – Apr 5, 2024 · Past
Shaheen Wirk
Other companies: Corvex, Inc. (Director · Since at least Jan 2, 2025)
Director · Apr 15, 2025 – Apr 17, 2025 · Past
Thomas Charles Reilly
Other companies: Amarin Corporation plc (EVP and CFO · Jun 30, 2022 – Jul 1, 2024 · Past)
Chief Financial Officer · Oct 1, 2020 – Mar 3, 2022 · Past
Avi Daniel ConnChief Financial Officer · Since at least Apr 15, 2025
Christopher PosnerPRESIDENT AND CEO, Director · Nov 2, 2023 – Feb 28, 2025 · Past
Dan ConnChief Financial Officer · Since at least Nov 4, 2026
David TweardyCo-Founder · Since at least Nov 4, 2026
Dean SlagelDirector · Jun 15, 2016 – Jun 29, 2017 · Past
Derek T ChalmersPresident & CEO, Director · Jan 6, 2016 – Sep 7, 2021 · Past
Frederique Ph D MenzaghiCHIEF SCIENTIFIC OFF,SVP-R&D · Jan 30, 2014 – Feb 1, 2024 · Past
Imran AlibhaiChief Executive Officer · Since at least Apr 15, 2025
Jeffrey Leroy LarsonSVP, Research & Development · Apr 15, 2025 – Apr 17, 2025 · Past
John KauhChief Medical Officer · Since at least Apr 15, 2025
Josef SchoellChief Financial Officer · Jan 30, 2014 – Jul 26, 2017 · Past
Kari Anne RowlandVice President, Clinical Operations · Since at least Nov 5, 2026
Michael T. LewisCo-Founder & Professor, Molecular and Cellular Biology and Radiology · Since at least Nov 4, 2026
Richard MakaraVP, Head of Accting;Controller · Jun 15, 2022 – Jun 15, 2022 · Past
Ron DePinhoCo-Founder & Chairman of Scientific Advisory Board · Since at least Nov 4, 2026
Scott TerrillionSEC'Y; CHIEF COMPLIANCE & G.C. · May 1, 2017 – Feb 28, 2025 · Past
Sofia de AchavalVice President, Development · Since at least Nov 5, 2026
Stephen O’BrienVP, Finance and Corporate Controller · Since at least Apr 15, 2025
Sujal ShahChairman of the Board · Since at least Apr 15, 2025
Susan ShiffDirector · Since at least Jun 26, 2020
Wallace HallBoard Member · Since at least Nov 5, 2026
Wallace L Hall JrDirector · Since at least Apr 15, 2025
Yixin Joseph ChenVice President, CMC · Since at least Apr 15, 2025

Open People

Log in to ask 6ix AI your own questions about Tvardi Therapeutics, Inc.